Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
FDA approval in the US is projected for late 2026 to early 2027, with Health Canada timelines typically following six to twelve months after that
Retatrutide is a multi-receptor agonist peptide currently in research for significant weight loss and metabolic improvement
The dose-response curve has largely flattened by 4 to 6 mg, while heart-rate and gastrointestinal costs continue to rise above it
Effectiveness in the treatment of diabetes and obesity In type 2 diabetes, GLP-1 receptor agonists are used to improve glycaemic control (often in combination with other medicines) and frequently result in weight loss
Most patients begin noticing visible weight changes within the first 4 to 6 weeks of treatment
US$ 22.09
US$ 24.75
US$ 29.58
US$ 29.57
